Analyst Price Targets — MAZE
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| January 19, 2026 5:12 pm | — | BTIG | $46.00 | $40.77 | TheFly | Maze Therapeutics price target raised to $46 from $37 at BTIG |
| December 19, 2025 1:07 pm | Debjit Chattopadhyay | Guggenheim | $46.00 | $41.92 | TheFly | Maze Therapeutics price target raised to $46 from $34 at Guggenheim |
| December 4, 2025 10:32 am | — | Wells Fargo | $55.00 | $41.49 | TheFly | Maze Therapeutics initiated with an Overweight at Wells Fargo |
| December 3, 2025 2:06 pm | — | H.C. Wainwright | $60.00 | $38.75 | TheFly | Maze Therapeutics price target raised to $60 from $50 at H.C. Wainwright |
| November 13, 2025 9:08 pm | — | Raymond James | $48.00 | $31.84 | TheFly | Maze Therapeutics initiated with a Strong Buy at Raymond James |
| September 15, 2025 10:42 am | Debjit Chattopadhyay | Guggenheim | $34.00 | $23.25 | TheFly | Maze Therapeutics price target raised to $34 from $19 at Guggenheim |
| September 2, 2025 10:38 am | — | BTIG | $30.00 | $15.32 | TheFly | Maze Therapeutics initiated with a Buy at BTIG |
| July 8, 2025 1:15 pm | Laura Chico | Wedbush | $17.00 | $13.31 | TheFly | Wedbush bullish on Maze Therapeutics, initiates with an Outperform |
Latest News for MAZE
SOUTH SAN FRANCISCO, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with kidney and metabolic diseases, today announced that Jason Coloma, Ph.D.
Shares of Maze Therapeutics, Inc. (NASDAQ: MAZE - Get Free Report) have been assigned a consensus rating of "Buy" from the eleven analysts that are presently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, seven have issued a buy rating and three have issued a strong buy
Chief Medical Officer Harold Bernstein exercised 15,000 shares, which were sold immediately for a total transaction value of approximately $690,300 on Feb. 2, 2026. Maze Therapeutics recently hit its one-year anniversary on the market, posting 174% growth over that period.
Maze Therapeutics (NASDAQ: MAZE) is advancing a genetics-driven approach to drug development, using human genetic analyses to identify gene variants linked to disease and then applying those insights to small-molecule programs focused primarily on kidney and metabolic disorders, CEO Jason Coloma said at Guggenheim's 2026 Emerging Biotech Summit. Coloma highlighted two clinical-stage programs as near-term priorities:
SOUTH SAN FRANCISCO, Calif., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with kidney and metabolic diseases, today announced that Jason Coloma, Ph.D.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for MAZE.
U.S. House Trading
No House trades found for MAZE.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.